P1282: MOCRAVIMOD IMPROVES OVERALL SURVIVAL IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

• Michael Medinger,
• Jakob Passweg,
• Christoph Bucher,
• Juergen Finke,
• Urs Schanz,
• Christos Stylianou,
• Simone Dertschnig,
• Malika Souquières,
• Stephan Oehen,
• Elisabeth Kueenburg,
• Dominik Heim

Affiliations

Michael Medinger

1 Universitätsspital Basel, Hematology, Basel, Switzerland

Jakob Passweg

1 Universitätsspital Basel, Hematology, Basel, Switzerland

Christoph Bucher

1 Universitätsspital Basel, Hematology, Basel, Switzerland

Juergen Finke

2 University of Freiburg, Medical Center, Freiburg, Germany

Urs Schanz

3 University Hospital of Zürich, Medical Oncology and Hematology, Zürich, Switzerland

Christos Stylianou

4 ClinBAY Ltd., Limasol, Cyprus

Simone Dertschnig

5 Priothera, St. Louis, France

Malika Souquières

5 Priothera, St. Louis, France

Stephan Oehen

5 Priothera, St. Louis, France

Elisabeth Kueenburg

5 Priothera, St. Louis, France

Dominik Heim

1 Universitätsspital Basel, Hematology, Basel, Switzerland